World Cancer Diagnostics Report 2021: Investments and Financing Agreements for Cancer Diagnostics Companies

News provided by

Dec 29, 2021, 14:00 ET

DUBLIN, Dec. 29, 2021 /PRNewswire/ -- The "World Market for Cancer Diagnostics, 2021" report has been added to ResearchAndMarkets.com's offering.

Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The World Market for Cancer Diagnostics, as well as relevant industry merger data, provides an authoritative and complete analysis of the cancer testing industry, with expert market sizing and opportunity assessment.

The report contains detailed market data on the following IVD segments for their use in cancer diagnostics:

Immunoassay - tumor markers
Molecular - cancer assays
Molecular - histology
Molecular - HPV
CTCs

This report contains

Investments and Financing Agreements For Cancer Diagnostics Companies
Selected Agreements Between Cancer Diagnostic Companies
Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies
Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies
Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations
Selected Acquisitions of Cancer Diagnostic Companies
Complete Market and Trend Analysis

The phenomenon of test personalization comes under many guises as pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest-growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive.

New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them.

Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies

This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemia - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis.

The emphasis is on in vitro diagnostic tests, however, a discussion of the role of diagnostics in cancer management must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis.

Key Topics Covered:

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER 2: INTRODUCTION AND OVERVIEW

Histology And Cytology In Situ Hybridization (ISH)
Immunoassays
Polymerase Chain Reaction (PCR)
Companion Diagnostics
Predictive Biomarker Tests For Drug-Gene Match
DNA And RNA Variants
Molecular Diagnostics In Hereditary Cancer Diagnosis
Cancer Markers In Widespread Usage

CHAPTER 3: MARKET TRENDS

Growth In Precision Medicine, Companion Diagnostics, Related Applications
Pharmacodiagnostic Tests
Companies Offering Liquid Biopsy-Based Molecular Cancer Assays
Liquid Biopsy-Based Non-Invasive Cancer Molecular Diagnostics
Circulating Tumor Cell (CTC) Tests
Sample Collection Products
Exosome Sequencing
Next-Generation Sequencing Tests
Whole-Genome Sequencing
Exome Sequencing
RNA Sequencing
Regulatory Influences
Advanced Histology Techniques
Automation Of Histology
Artificial Intelligence
Mass Spectrometry
Regulatory And Reimbursement Trends
Reimbursement Breakthroughs And Challenges
Next Generation Sequencing Coverage
Companion Diagnostics Seeing Development In Regulations
Food And Drug Administration
Directive 98/79/EC
Health Canada Changes And Forecasted Action
International Growth Opportunities

CHAPTER 4: MARKET REVENUES AND FORECAST

Molecular Cancer Test Regional Distribution
Histology and Cytology
Histology Regional Distribution
Molecular Cancer Diagnostics Segment By Technology/Method
HPV Regional Distribution
Drivers And Challenges
Clinical Utility of Molecular Diagnostics
Technological Advancements Including NGS Adopted Incrementally

CHAPTER 5: COMPETITIVE ANALYSIS

Immunoassay Competitive Trends
IHC Market
Competition in ISH
Molecular Cancer Diagnostics Landscape
HPV
Liquid Biopsy And CTCs
Recent Deals And Collaborations

CHAPTER 6: COVID-19 IMPACT

Minimal Ongoing Significant Disruptions

CHAPTER 7: CORPORATE PROFILES

Abbott Diagnostics
Agendia BV
Agilent Technologies
ARUP Laboratories
Asuragen Inc.
Beckman Coulter (Danaher)
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Biocartis
Biocept, Inc.
Biodesix
bioMerieux Inc.
BioReference Laboratories
Biotheranostics, Inc. (Hologic)
Danaher Corporation
DiaSorin S.p.A
Enzo Biochem Inc.
Epic Sciences
Epigenomics AG
Exact Sciences Corp.
Exosome Diagnostics, Inc
Foundation Medicine, Inc.
Guardant Health, Inc.
Helomics Corporation
Hologic, Inc.
Illumina, Inc.
LabCorp
Leica Biosystems (Danaher)
LungLife AI
Mayo Medical Laboratories
MDxHealth SA
Menarini-Silicon Biosystems
Myriad Genetics, Inc.
Natera
NeoGenomics
OPKO Health, Inc.
Pacific Biosciences
Qiagen N.V.
Quest Diagnostics
Roche Diagnostics
Sysmex Corp.
Thermo Fisher Scientific Inc.
Trovagene, Inc.
Ventana Medical Systems (Roche)
Veracyte

For more information about this report visit https://www.researchandmarkets.com/r/falpn9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets